- Home
- NSTS vs CELU Comparison
NSTS vs CELU Comparison
Compare NSTS & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- CELU
- Stock Information
- Founded
- NSTS 1921
- CELU 2016
- Country
- NSTS United States
- CELU United States
- Employees
- NSTS N/A
- CELU N/A
- Industry
- NSTS Savings Institutions
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- CELU Health Care
- Exchange
- NSTS Nasdaq
- CELU Nasdaq
- Market Cap
- NSTS 63.0M
- CELU 64.3M
- IPO Year
- NSTS N/A
- CELU N/A
- Fundamental
- Price
- NSTS $11.74
- CELU $2.11
- Analyst Decision
- NSTS
- CELU Buy
- Analyst Count
- NSTS 0
- CELU 1
- Target Price
- NSTS N/A
- CELU $6.00
- AVG Volume (30 Days)
- NSTS 1.8K
- CELU 118.0K
- Earning Date
- NSTS 08-14-2025
- CELU 08-29-2025
- Dividend Yield
- NSTS N/A
- CELU N/A
- EPS Growth
- NSTS N/A
- CELU N/A
- EPS
- NSTS N/A
- CELU N/A
- Revenue
- NSTS $9,435,000.00
- CELU $44,590,000.00
- Revenue This Year
- NSTS N/A
- CELU $23.29
- Revenue Next Year
- NSTS N/A
- CELU N/A
- P/E Ratio
- NSTS N/A
- CELU N/A
- Revenue Growth
- NSTS 69.39
- CELU 4.45
- 52 Week Low
- NSTS $9.37
- CELU $1.00
- 52 Week High
- NSTS $13.32
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- NSTS 32.60
- CELU 32.18
- Support Level
- NSTS $11.90
- CELU $2.23
- Resistance Level
- NSTS $11.99
- CELU $4.00
- Average True Range (ATR)
- NSTS 0.06
- CELU 0.32
- MACD
- NSTS -0.01
- CELU -0.22
- Stochastic Oscillator
- NSTS 0.00
- CELU 4.23
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.